Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Cyclophosphamide/hydroxycarbamide/imatinib

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang L, et al. Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. Brazilian Journal of Medical and Biological Research 48: 583-587, No. 7, 14 Jul 2015. Available from: URL: http://doi.org/10.1590/1414-431X20154557 Wang L, et al. Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. Brazilian Journal of Medical and Biological Research 48: 583-587, No. 7, 14 Jul 2015. Available from: URL: http://​doi.​org/​10.​1590/​1414-431X20154557
Metadaten
Titel
Cyclophosphamide/hydroxycarbamide/imatinib
Lack of efficacy: case report
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15050-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Artesunate

Case report

Iron sucrose

Case report

Fluorouracil